Jazz Pharmaceuticals
JAZZ
#1737
Rank
$8.17 B
Marketcap
$129.44
Share price
-1.21%
Change (1 day)
-14.65%
Change (1 year)

P/E ratio for Jazz Pharmaceuticals (JAZZ)

P/E ratio as of October 2023 (TTM): -91.8

According to Jazz Pharmaceuticals's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -91.8014. At the end of 2021 the company had a P/E ratio of -23.7.

P/E ratio history for Jazz Pharmaceuticals from 2007 to 2022

PE ratio at the end of each year

Year P/E ratio Change
2021-23.7-161.84%
202038.3136.52%
201916.2-2.56%
201816.60.33%
201716.6-2.17%
201616.9-35.2%
201526.1-85.16%
2014176

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
28.1-130.65%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
21.7-123.65%๐Ÿ‡บ๐Ÿ‡ธ USA
-0.0008-100.00%๐Ÿ‡ฎ๐Ÿ‡ช Ireland
-5.10-94.44%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.